Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates
Summary: HER2 is a common target for antibody-drug conjugates (ADCs) being developed against breast cancer, due in part to the success of ADCs such as Kadcyla® and Enhertu® in the clinic. Follow-on candidates targeting HER2 are leveraging a variety of innovations, for example novel payloads and linkers, in order to improve patient outcomes. In a recent study published in Molecular Cancer Therapeutics, Catalent Biologics experts share the results of preclinical studies on their HER2-targeted ADC, CAT-01-106. This article highlights those findings in the context of the anti-HER2 ADC pipeline.